Targeted Breast Cancer Drugs Show Promise

Promising results from two studies involving drug treatments potentially offer new hope for breast cancer patients.


There is promising news on breast cancer. We have the results of two new studies involving targeted drug treatments.

CBS News correspondent Dr. Jon LaPook examined the way these experimental therapies work.

When 66-year-old Debbera Drake was diagnosed with advanced breast cancer in 2007. It had already spread to her lungs. Then it went to her brain, and her doctor said she probably wouldn't survive.

"I wasn't as scared as I was sad because I love my life, I love my family. And I thought, I thought I don't want to leave them soon," Drake said.

Today's two drug studies offer people like Drake new options for fighting advanced breast cancer. Unlike traditional chemotherapy, these drugs target cancer cells while leaving normal, healthy ones alone.

"These two findings will change practice that will affect close to 8-0 % of our patients with metatsastic breast cancer. That's huge news on its own," said Dr. Jose Baselga, the principal researcher.

One treatment combined Aromasin, which blocks production of the cancer fueling hormone Estrogen with Afinitor, which cuts off a tumor's blood supply and also attacks the inside of cancer cells.

Women receiving both Aromasin and Afinitor went about four months longer without their cancer progressing than those receiving just one.

The treatments are personalized, only working for women with specific types of breast cancer.

"These patients feel better, these patients have fewer side effects, these patients can carry on normal lives," Dr. Baselga said.

And there's likely to be more discoveries ahead. Last month, we visited Dr. Baselga's lab, where scientists use the world's largest library of tumors to discover mutations in cancer cells that can be attacked by new drugs.

The second trial combined standard chemotherapy with two newer drugs specifically targeting the surface of breast tumor cells. The cancer was held in check for an additional six months.

Both new combinations must still be approved by the FDA.

KKTV firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKTV 11 News.

If you believe that any of the comments on our site are inappropriate or offensive, please tell us by clicking “Report Abuse” and answering the questions that follow. We will review any reported comments promptly.

powered by Disqus
KKTV 520 E. Colorado Colorado Springs, CO 80903 Office: (719) 634-2844 Fax: (719) 632-0808 News Fax: (719) 634-3741
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 135239283 -
Gray Television, Inc.